RESEARCH ARTICLE


False-Positive Diagnostics of Bordetella Pertussis using IS481 PCR is Limited in Danish Patients



Silje V. Hoegh, Charlotte N. Agergaard*, Marianne N. Skov, Michael Kemp
Department of Clinical Microbiology, Odense University Hospital, Winsløwparken 21, 2, DK-5000 Odense, Denmark.


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 295
Abstract HTML Views: 247
PDF Downloads: 148
ePub Downloads: 124
Total Views/Downloads: 814
Unique Statistics:

Full-Text HTML Views: 191
Abstract HTML Views: 140
PDF Downloads: 105
ePub Downloads: 80
Total Views/Downloads: 516



© 2019 Hoegh et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Clinical Microbiology, Odense University Hospital, Winsløwparken 21, 2, DK-5000 Odense C, Denmark; Tel: +45 6541 1347; E-mail: charlotte.agergaard@rsyd.dk


Abstract

Background:

Bordetella pertussis is routinely detected using real-time PCR based on the multicopy insertion sequence IS481, which is not specific for Bordetella pertussis.

Objective:

The aim of this retrospective study was to evaluate the proportion of other Bordetella species misidentified as Bordetella pertussis using IS481-targeted real-time PCR.

Methods:

Clinical specimens from 228 Danish patients (median age 15 years, 0 to 90 years old) formerly identified as positive for Bordetella pertussis (IS481+) by routine PCR in 2011-2015, were subjected to real-time PCR targeting the insertion sequences IS1002 and IS1001.

Results:

The results showed that 2.3% of the samples were false-positive for Bordetella pertussis.

Conclusion:

In conclusion, we found that misidentification of Bordetella pertussis using IS481 PCR is limited in Danish patients.

Keywords: Bordetella pertussis, Real-time PCR, IS481, IS1002, IS1001, False-positive.



1. INTRODUCTION

Whooping cough is a highly contagious respiratory disease. It causes both local outbreaks and epidemics despite being vaccine-preventable. Whooping cough continues to be a significant cause of morbidity and infant mortality worldwide. Ten different species compose the genus Bordetella, four of which are known to infect humans: Bordetella pertussis, Bordetella parapertussis, Bordetella holmesii and Bordetella bronchiseptica. Humans are the sole reservoir for B. pertussis, which is the primary cause of whooping cough or pertussis. B. parapertussis may be responsible for up to 20% of the cases of pertussis-like disease, but the illness is often less severe than the one caused by B. pertussis [1]. B. holmesii is associated with bacteremia, infective endocarditis, and respiratory illness, particularly in functionally or anatomically asplenic patients. However, B. holmesii has also been isolated from nasopharyngeal specimens of immunocompetent individuals with pertussis-like illness. B. bronchiseptica is primarily an animal pathogen, but will occasionally infect humans and, like B. holmesii, B. bronchiseptica, may cause invasive disease. Known cases describe bacteremia, peritonitis and respiratory tract infection in immunocompromised patients [2, 3].

PCR is the prevailing method used for detection of Bordetella pertussis in clinical samples, being fast, sensitive and less laborious compared to culturing. Molecular detection of B. pertussis is commonly based on insertion sequence IS481, which is present in multiple copies (>50 copies) in the B. pertussis genome, increasing the sensitivity of the PCR [4]. A high sensitivity of the assay is necessary in order to document the high incidence of pertussis, continuously found in the local population [5]. However, the target sequence IS481 is also present in the genomes of B. holmesii (about 8-10 copies), and of some B. bronchiseptica [1]. In this study, a method described by Roorda et al. [6] involving a PCR assay targeting IS1001 and IS1002 as well as IS481 is used for specific detection of B. pertussis. IS1002 is present in the genomes of B. pertussis and B. parapertussis, while IS1001 is found in all B. parapertussis and in a few B. bronchiseptica. Thus, a specimen containing B. pertussis will be positive for IS481 and IS1002 and negative for IS1001 Table 1 [1].

Table 1. Bordetella species and presence of insertion sequences.
Presence/No. of Copies per Genome
Species IS481 IS1001 IS1002
B. pertussis +/>50 - +/4-10
B. parapertussis - +/~20 +/9
B. holmesii +/8-10 - -
B. bronchiseptica -a -a/1-7 -

The objective of this study was to retrospectively evaluate the proportion of other Bordetella species potentially misidentified as B. pertussis in patient samples collected between 2011 and 2015 in our region using IS481 based real-time PCR (rt-PCR).

2. MATERIALS AND METHODS

Clinical specimens were sputum and throat swabs collected from 228 Danish patients identified as positive for B. pertussis by routine PCR in 2011-2015. Stored extracted DNA (NucliSENS® easyMAG®, bioMérieux) previously positive for IS481 was reanalyzed by rt-PCR targeting the insertion sequences IS1002 and IS1001. Samples had been kept for quality control and were anonymized, therefore patients did not have to provide informed written consent.

Target sequences of the PCR were IS481, IS1001, and IS1002 Table 2. Phocine Herpes Virus (PhHV) was added to the samples as internal control in order to monitor the DNA extraction as well as the PCR amplification efficiency. Furthermore, negative control, as well as positive target controls were included in each run.

PCR assays for detection of IS481 were performed in 25 µl reaction volume containing 1× Lightcycler® 480 Probes master (Roche), 0.5 µM of IS481 forward and reverse primers, 0.2 µM of the IS481 probe and 5 µl extracted DNA. The amplification of IS1001, IS1002 and PhHV were run in separate reaction mixes containing 1× Lightcycler® 480 Probes master (Roche), 1.0 µM of each primer, 0.2 µM of the probe and 5 µl of extracted DNA. Amplification was carried out on a Lightcycler® 480 (Roche). The temperature profile included initial denaturation of 10 min at 95°C followed by 45 cycles of 95°C for 10 sec, 60°C for 30 sec, and 72°C for 1 sec. The Crossing Point (Cp) values were determined by the 2nd Derivative Max method using the Lightcycler® 480 software. A Cp value <40 combined with an acceptable curve was considered positive.

3. RESULTS

The Cp values obtained from the IS481 PCR-positive samples were on average 5.3 Cp values lower than the Cp values obtained from the IS1002 PCR, presumably due to differences in copy number of the target sequence (approximately >50 and 10 copies, respectively). Of the 228 clinical samples positive for B. pertussis (IS481+) by routine PCR, we therefore only included samples with a Cp value of <32 in the IS481 PCR in order to rule out that any negative result in the IS1002 PCR was due to lower sensitivity. 131 samples obtained a Cp value <32 in the IS481 PCR. 128 of these were also positive in the IS1002 PCR confirming the species identity as B. pertussis (IS481+ and IS1002+). Hence the three IS1002 negative samples were subjected to PCR targeting IS1001; all three were found negative (IS481+, IS1002- and IS1001-) and therefore did not contain B. parapertussis or IS1001 positive B. bronchiseptica DNA. Thus, three samples (2.3%) had been misidentified as B. pertussis. Presumably, these samples contained either B. holmesii or, less likely, B. bronchiseptica.

Patients had a median age of 15 years (0-90 years-old) with 59% of females.

Table 2. Real-time PCR assays targeting the three IS elements and the internal control Phocine Herpes virus (PhHV).
PCR Assay Label Sequence (5’-3’) References
IS481 Forward primer CGG ATG AAC ACC CAT AAG CAT [14]
Reverse primer CGA TCA ATT GCT GGA CCA TTT
Probe FAM-CCC GAT TGA CCT TCC TAC GTC GAC TC-BHQ1
IS1001 Forward primer AAT TGC TGC AAG CCA ACC A [6]
Reverse primer CCA GAG CCG TTT GAG TTC GT
Probe FAM-ACA TAG ACC GTC AGC AG-MGB
IS1002 Forward primer CTA GGT CGA GCC CTT CTT GTT AAC [6]
Reverse primer GCG GGC AAG CCA CTT GTA
Probe FAM-CAT CGT CCA GTT CTG TTG CAT CAC CC-BHQ1
PhHV Forward primer GGG CGA ATC ACA GAT TGA ATC [15]
Reverse primer GCG GTT CCA AAC GTA CCA A
Probe FAM-TTT TTA TGT GTC CGC CAC CAT CTG GAT C-BHQ1

4. DISCUSSION

In this retrospective study, we found that in 131 samples identified with routine non-discriminating B. pertussis IS481 rt-PCR, the bacterium had been misidentified in three samples. The three samples all originated from male adolescents (ages 14, 15 and 21 years-old) and presumably contained B. holmesii. This is consistent with observations from France and the Netherlands of B. holmesii in nasopharyngeal-samples from adolescents and young adults [7, 8]. We found a false-positive rate of 2.3%. Other studies have reported a much higher incidence of false-positive B. pertussis. Njamkepo et al. [7] found that the proportion of B. holmesii falsely identified as B. pertussis with IS481 PCR was 20.3% of samples collected from French adolescents and adults (n=59). From Chilean patients with suspected pertussis Miranda et al. [9] detected B. holmesii DNA in 11.1% of IS481-positive samples (n=99). In Norway, Reinton et al. [10] detected B. holmesii DNA in 5.8% of B. pertussis positive samples (n=87) and no B. bronchiseptica DNA in 375 other B. pertussis positive samples. In other European countries, no B. holmesii DNA was detected in nasopharyngeal samples from Finnish (n=2804), Dutch (n=6903) and Belgian (n=1493) patients with pertussis-like illness [3, 11]. Moreover, in Swiss patients, no B. holmesii DNA was detected in 194 B. pertussis positive samples [2].

The implications of misidentification of B. pertussis are currently unclear. Still, correct identification of B. pertussis is considered important for several reasons. Firstly, in vitro studies suggest that macrolides used to treat B. pertussis infections are less effective against B. holmesii and probably also against B. bronchiseptica. Secondly, a false-positive B. pertussis may cause prescription of unnecessary post-exposure prophylaxis, and thirdly, B. holmesii or B. bronchiseptica mis-diagnosed as B. pertussis may suggest vaccine failure and lead to excessive public health interventions [1-3, 12].

It has been suggested to use multiple target PCR assays for detection of B. holmesii and B. brochiseptica in concordance with IS481 to rule out false-positive B. pertussis or to use confirmatory PCR assays for specific detection of B. pertussis [13-15]. However, this will significantly increase workload, cost and turnaround time. As the confirmatory assays are less sensitive than the IS481 PCR, they may come out negative in samples with low amounts of B. pertussis, resulting in false-negative reports. In a clinical setting, sensitivity, as well as rapid diagnostics must be prioritized to ensure appropriate treatment and prevention of further transmission.

CONCLUSION

We have shown that false-positive diagnostics of B. pertussis using IS481 PCR is limited in Danish patients. This is consistent with the results from other studies [2, 3, 11, 12]. Our priority remains to diagnose B. pertussis infection. Thus, the rt-PCR assay targeting IS481 combines high sensitivity with an acceptable false-positive rate of 2.3% if the Cp is set to <32. Supplementary assays should not be necessary on a routine basis but may be applied in situations with clinical suspicion of false-positive results.

ABBREVIATIONS

IS = Insertion Sequence
PhHV = Phocine Herpes Virus
Cp = Crossing Point

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

HUMAN AND ANIMAL RIGHTS

No animals/humans were used for studies that are the basis of this research.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors have no conflict of interests.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Loeffelholz M. Towards improved accuracy of Bordetella pertussis nucleic acid amplification tests. J Clin Microbiol 2012; 50(7): 2186-90.
[2] Pittet LF, Emonet S, François P, et al. Diagnosis of whooping cough in Switzerland: differentiating Bordetella pertussis from Bordetella holmesii by polymerase chain reaction. PLoS One 2014; 9(2): e88936.
[3] Van den bossche D, De Bel A, De Smet D, et al. Prevalence of Bordetella holmesii and Bordetella bronchiseptica in respiratory tract samples from Belgian patients with pertussis-like symptoms by sensitive culture method and mass spectrometry. Acta Clin Belg 2013; 68: 341-8.
[4] Reischl U, Lehn N, Sanden GN, Loeffelholz MJ. Real-time PCR assay targeting IS481 of Bordetella pertussis and molecular basis for detecting Bordetella holmesii. J Clin Microbiol 2001; 39(5): 1963-6.
[5] Statens serum institut, Denmark, EPI-news No 16, April 2016 2016http://wwwssidk/English/News/EPI-NEWS/2016/No%2016%20-%202016aspx [Accessed 2018 November 2];
[6] Roorda L, Buitenwerf J, Ossewaarde JM, van der Zee A. A real-time PCR assay with improved specificity for detection and discrimination of all clinically relevant Bordetella species by the presence and distribution of three Insertion Sequence elements. BMC Res Notes 2011; 4: 11.
[7] Njamkepo E, Bonacorsi S, Debruyne M, Gibaud SA, Guillot S, Guiso N. Significant finding of Bordetella holmesii DNA in nasopharyngeal samples from French patients with suspected pertussis. J Clin Microbiol 2011; 49(12): 4347-8.
[8] Mooi FR, Bruisten S, Linde I, et al. Characterization of Bordetella holmesii isolates from patients with pertussis-like illness in The Netherlands. FEMS Immunol Med Microbiol 2012; 64(2): 289-91.
[9] Miranda C, Porte L, García P. Bordetella holmesii in nasopharyngeal samples from Chilean patients with suspected Bordetella pertussis infection. J Clin Microbiol 2012; 50(4): 1505.
[10] Reinton N, Manley L, Tjade T, Moghaddam A. Respiratory tract infections during the 2011 Mycoplasma pneumoniae epidemic. Eur J Clin Microbiol Infect Dis 2013; 32(6): 835-40.
[11] Antila M, He Q, de Jong C, et al. Bordetella holmesii DNA is not detected in nasopharyngeal swabs from Finnish and Dutch patients with suspected pertussis. J Med Microbiol 2006; 55(Pt 8): 1043-51.
[12] Guthrie JL, Robertson AV, Tang P, Jamieson F, Drews SJ. Novel duplex real-time PCR assay detects Bordetella holmesii in specimens from patients with Pertussis-like symptoms in Ontario, Canada. J Clin Microbiol 2010; 48(4): 1435-7.
[13] Probert WS, Ely J, Schrader K, Atwell J, Nossoff A, Kwan S. Identification and evaluation of new target sequences for specific detection of Bordetella pertussis by real-time PCR. J Clin Microbiol 2008; 46(10): 3228-31.
[14] Chan EL, Antonishyn N, McDonald R, et al. The use of TaqMan PCR assay for detection of Bordetella pertussis infection from clinical specimens. Arch Pathol Lab Med 2002; 126(2): 173-6.
[15] Niesters HG. Quantitation of viral load using real-time amplification techniques. Methods 2001; 25(4): 419-29.